Athira Pharma (ATHA) Investor Presentation - Slideshow

Company Overview - Athira Pharma is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration[7] - The company's lead asset, ATH-1017, is in a potentially pivotal trial for Alzheimer's disease, with topline data expected from the LIFT-AD trial by late 2022 and from the ACT-AD trial by early 2022[9] - Athira is expanding its pipeline of novel, small molecule compounds designed to improve neuronal health, targeting CNS degenerative disorders, PNS disorders, and neuropsychiatric indications[11, 14] Scientific Rationale - The HGF/MET system is critical to normal brain function, with MET expression reduced by 75% in the hippocampus and 25% in the frontal cortex of AD patients[23, 25] - ATH-1017 is designed to promote the HGF/MET neurotrophic system, resulting in multi-modal downstream effects and acute and sustained effects on synaptic and network function[26] - Clinical trial designs assess the effects of ATH-1017's novel mechanism of action (MOA) using qEEG and ERP P300, non-invasive methods that provide a direct measure of brain activity[34] Clinical Trial Data and Design - Phase 1b trial data showed that ATH-1017 treatment improved P300 latency in AD subjects, with a significant change from baseline observed on Day 8 in the treated group compared to placebo[47, 54] - The Phase 2/3 LIFT-AD trial is a 26-week randomized, double-blind treatment study with 240-300 mild-to-moderate AD dementia subjects, using a Global Statistical Test (GST) as the primary endpoint[60] - ATH-1020, an orally bioavailable small molecule, is in development for neuropsychiatric indications and has demonstrated anti-depressant effects in animal models[89, 90] Financial Position - Athira Pharma reported a strong capital position with $357.7 million in cash, cash equivalents, and marketable securities as of March 31, 2021, compared to $268.2 million as of December 31, 2020[95] - In the first quarter of 2021, Athira completed a follow-on public offering and raised total gross proceeds of $103.5 million[95]